FULL YEAR RESULTS - 13TH MARCH 2024

For a future made possible by science.



Disclaimer.

The communication of this presentation may be restricted by law; it is not intended for distribution to, or use by any person in any jurisdiction where such distribution or use would be unlawful. Any person into whose possession any part of this presentation comes is required by IP Group plc. (the "Company") to inform himself/herself about and to observe any applicable restrictions in his/her respective jurisdiction.

This presentation is for information purposes only and does not constitute an offer of, or a solicitation to purchase or subscribe for, any securities in which such offer or solicitation is unlawful or to any person to whom it is unlawful to make such offer or solicitation. This presentation or any part of it or the fact of its distribution shall not form the basis of, or be relied on in connection with, any contract commitment or investment decision in relation thereto nor does it constitute a recommendation regarding the securities of the Company. No person must construe the information contained in this presentation as legal, business, tax or investment advice. Investors and prospective investors in the securities of the Company are required to make their own independent investigation and appraisal of the business and financial condition of the Company and the nature of the securities, and consult his/her own independent counsel, business advisor, tax advisor, investment advisor or any other authorised advisors as to the legal, business, tax, investment or any other matters pertaining to the Company and the securities of the Company.

The statements contained in this presentation are made as at the date of this presentation. The distribution of this presentation shall under no circumstances imply that there shall not be a change in the Company's affairs since the date of this presentation or that the information contained in this presentation is correct as of any date subsequent to the date of this presentation.

The Company or any member, employee, counsel, officer, director, representative, agent or affiliate of the Company does not have any obligation to update or otherwise revise any statements reflecting circumstances arising after the date of this presentation. To the extent permitted by applicable law, no representation or warranty, express or implied, is made by the Company or any member, employee, counsel, officer, director, representative, agent or affiliate of the Company as to the accuracy or completeness of any information contained in this presentation. No information contained in this presentation is, or shall be relied upon by any person as to its accuracy or completeness or as a promise or representation by the Company.

The Company expressly disclaims any and all liability that may be based on any information contained in this presentation and any errors or omissions herein. No person is authorised to give any information not contained in this presentation and any information not contained in this presentation must not be relied upon as having been authorised by or on behalf of the Company. Nothing contained in this presentation shall be deemed to be a profit forecast. This presentation may contain certain forward-looking statements, beliefs or opinions with respect of the financial condition and business operations of the Company as well as certain plans and objectives of the Company. By their nature, forwardlooking statements involve risk and uncertainty, because they depend on circumstances and events that may or may not occur in the future. Past performance of the Company cannot be relied on as a guide to future performance, and any actual results and developments may differ materially from those expressed in or implied by such forward-looking statements. The Company can give no assurance that such expectations will prove to have been correct and the Company therefore cautions any person not to place undue reliance on these forward-looking statements which speak only as at the date of this presentation.



Contents.

Overview

 $\mathbf{0}$

Maturing portfolio with multiple inflection points

03

Financial results


Summary and Q&A



Speakers.

			i. Hysata
Greg Smith. CEO	David Baynes. CFOO	Dr Sam Williams. Managing Partner, Life Sciences	Paul Barrett. Founder, CEO & Director at Hysata
ic group visionary ventures	ic group visionary ventures	ic group visionary ventures	. Hysata









Full Year Overview.



Maturing portfolio with multiple near-term inflection points.

Portfolio entering a milestone rich window

Sector specialists with investment focused on highest growth opportunities

Geographic focus on UK and Aus, decisive action on US & China

Total portfolio £0.7bn. capital raised



Financial strength maintained during challenging markets.

Group & portfolio well-funded Gross cash £227m NAV per share of 114.8p



Continued commitment to shareholder returns.

Committed to regular cash returns from exits

IR activity more than doubled

Further £20m buyback underway



Cash returned to £75m. shareholders since 2021





IP Group: industry pioneers.




Pioneered the model and catalysed an industry.

UK's most active investor in science and innovation companies.

io group


visionary ventures



Focused portfolio set to deliver.



Investment themes and value drivers.





High opportunity markets.

Healthier future.

Tech-enriched future.

Regenerative future.

- <u>Evaluate Pharma Outlook to 2028</u>
- EY Biopharma Firepower Report
- Markets and Markets 4. Sky Quest.com

X X O X O

"Carbonomics - The clean hydrogen revolution", Goldman Sachs McKinsey

Market drivers

Big Pharma looking for investment opportunities

- \$20bn+ p.a. pharma revenues at risk due to 'patent cliff'
- \$1.4tn Biopharma M&A Firepower²

The digital transformation is the most pervasive trend shaping our world

- \$40bn fraud detection and prevention market by 2025³
- Semiconductor memory market \$103bn in 2022, projected to grow to \$160bn+ by 2030⁴

Accelerating transition towards clean energy

- Green hydrogen: \$1.7tn investment in electrolysers needed by 2050⁵
- Autonomous vehicle software market to double by 2030 to \$80bn⁶



© IP GROUP PLC 2024 | FULL YEAR RESULTS



02Maturing portfolio with multiple inflection points



Healthier Future



Entering a milestone-rich window.

THERAPEUTICS PORTFOLIO	IP GROUP VALUE £m	COMPANY	2024	2025
	17.4	<u>artios</u>	 	Phase 2
	19.6	Crescendo	Phase 1/2	
ONCOLOGY	9.4		Phase 1/2	
ONCOLOGY	5.3			Phase 1/2
	7.6			Phase 1/2
	16.1	esitoidonaim		Phase 1b
	113.8	istesso	Phase 2b	
INFLAMMATION	15.8			Phase 2a
	4.0	Kynos Inerapeutics	Phase 1	
	19.2			Phase 3
OTHER	5.0	enterprize ² THERAPEUTICS		Phase 2a
	15.7	CENTESSA ³	Phase 2b	
	1.6	∧BLIVA ^₄	Phase 2/3	

*Timing reflects current best estimate of clinical readouts and is subject to change

1. <u>Based on a disclosed trial start date in 2024 we estimate trial completion in 2H 2025</u>

2. Based on a disclosure in the media we estimate first batch of data to come in mid-2025

3. Phase 2b interim data for SerpinPC and Phase 1 interim data for ORX750 is estimated in Q4 2024

4. Phase 2/3 interim data for KL1333 is estimated in 2H 2024



istesso

From disease modification to disease resolution.

Phase 2b data for leramistat (MBS2320) in rheumatoid arthritis, a \$25bn¹ market, on target; in 1H24

FDA fast-track and orphan drug designation for the treatment of idiopathic pulmonary fibrosis (IPF), a \$4bn² market and condition of high unmet need

IPF phase 2; results expected 2025

IP Group provided £15m, committing £25m in total, fully funding both trials

Note: As of 31 December 2023 % holding on an undiluted basis.

Based on Berenberg DrugBank analysis and GlobalData

2. Based on Citeline data






Tech-enriched



Al and Machine Learning Opportunity.





Our job is to make the world a safer place to transact. •

FEATURE

SPACE

Martina King

CEO

Leading predictive analytics for fraud and cybercrime prevention.

Applied AI solution identifies abnormal transactions to automatically evaluate financial crime risk

50bn events processed each year, protecting 500m consumers from risk

£34.4m revenues in 2022, growing significantly above market rate

Customers include blue-chip financial institutions such as HSBC, Worldpay and NatWest

Recurring revenues representing c.80%

Note: As of 31 December 2023 % holding on an undiluted basis







Regenerative Future.



17 © IP GROUP PLC 2024 | FULL YEAR RESULTS

••• Hysata

Redefining the economics of green hydrogen.

Green hydrogen is expected to supply 10%-15% of all energy in a net-zero global economy by 2050.

Highly efficient electrolysers enable economically viable green hydrogen

Hysata has developed a unique, patented electrolyser with proven 95% system efficiency versus the best incumbents at 75%

Strong market pull and company on track to deliver commercial scale systems with key customers in near future

Deep experience in the team across electrolysers and high-volume manufacturing

Disruptive product proposition underpinned by low capex, minimal EPC and design for mass manufacturability for hyperscaling







Financial results

Strong balance sheet with well-funded portfolio



Summary financials.

Gross Cash.

Net Asset Value (NAV). £1,190m (FY22 £1,376m)

Return on NAV.

£227m (FY22 £241.5m) **114.8pps** (FY22132.9pps)



Share Buyback Announced.

£20m (FY22 nil)


We continue to navigate carefully through difficult markets. With £227m gross cash and only 13% of our portfolio needing to raise money in 2024, we are well-positioned for an improvement in investor appetite.

David Baynes

CFOO




Drivers of private portfolio fair value changes.






Results: Balance sheet - net assets.




ip group

Total portfolio composition and concentration.




Portfolio concentration:






The Group remains well funded.





And our portfolio remains well funded.





Portfolio valuation approach.



	Primary Approach	Description	Proportion of NAV
	Quoted market prices	Bid price at valuation date	17%
	Funding transaction	Last funding round price, without adjustment	30%
	Adjusted financing	Valuation based primarily on recent financing price, adjusted upwards (5 companies) or downwards (14 companies) based on positive or negative performance since last priced financing	26%
	Future market/ commercial events	Near-term event, typically a funding round or exit which has documented terms but has not completed at the valuation date	2%
	Revenue multiples	Estimate of company Enterprise Value based on actual or forecast revenue and a revenue multiple	7%
	Discounted Cashflow (DCF) Models	Estimate based on cashflow projections, probability and risk-weighted to the valuation date	11%



Typical order of preference based on degree of market input







FY22 private debt placing totalling

£120m

Partial repayment of EIB Debt adds

£105m

net headroom

Provided by UK institutional investors including Phoenix Group to support

SUSTAINABLE DEVELOPMENT

GCALS

sustainable investments



Drawn down in two tranches:

1. £60m 2022 2. £60m 2023




Repayment over three tranches:

£40m 2027
£40m 2028
£40m 2029



at 5.25% fixed interest

Continued commitment to shareholder returns.





S






Summary

For a future made possible by science





visionarv ventures

Focused, with significant inflection points ahead.



Maturing portfolio with multiple near-term inflection points.




Financial strength maintained during challenging markets.



Continued commitment to shareholder returns.









05 Appendices



1 Summary of strategy.

Accelerating the impact of science for a better future.

A future enhanced by the impact of transformative businesses we have identified, backed and grown as long-term partners.





2 Impact is in our DNA.


IMPACT AT OUR CORE

GROUP LEVEL IMPACT		PORTFOLIO LEVEL IMPACT		By the numbers.	
Impact on our communities.	Impact is a strategic driver for IP Group.	Tech-enriched future.	Regenerative future.	Healthier future.	£1.8bn¹ Backing science-based businesses
We actively work with local community groups to increase access to skills and opportunities for all	Impact is one of our five strategic pillars and is a fundamental component of our business model and corporate strategy	We back deeptech companies and future computing solutions, that enable the digital economy, and generate prosperity for all	We invest in science, addressing the global climate challenge, and back innovators and pioneers, creating revolutionary climate technology solutions	We invest in breakthrough therapeutics, which focus on cure and prevention rather than only treating symptoms	500+ companies backed across cleantech, life sciences and deeptech
IntoUniversity in	Signatory of: Principles for Responsible Investment	9 INDUSTRY, INNOVATION AND INFRASTRUCTURE	13 CLIMATE	3 GOOD HEALTH AND WELL-BEING	10k+ jobs created by the compan we have backed

We are investing today in science, addressing the world's greatest unmet challenges

nies

Note: The use by IP Group plc of any MSCI ESG research IIc or its affiliates ("MSCI") data, and the use of MSCI logos, trademarks, service marks or index names herein, do not constitute a sponsorship, endorsement, recommendation, or promotion of IP Group plc by MSCI. MSCI services and data are the property of MSCI or its information providers, and are provided 'as-is' and without warranty. MSCI names and logos are trademarks or service marks of MSCI. 1. £1.2bn NAV + £650m 3rd party AUM as of 31 December 2023.



35

φgroup visionary ventures

3 Board.



Sir Douglas Flint

Non-executive Chairman Previously Group Chairman of HSBC, spent 15 years as HSBC's Group Finance Director, joining from KPMG where he was a partner.



Dr Elaine Sullivan Non-executive Director 27 years' international pharmaceutical industry experience including Eli Lilly and AstraZeneca.





Aedhmar Hynes

Non-executive Director

Background in communications advising brands through digital transformation and technology disruption. Ranked among the 'PR Week' 50 most powerful communications professionals in the world.



Greg Smith

funds.

Chief Executive Officer

Decade as Group CFO driving strategy, scale and geographic expansion. Deep experience in investment appraisal, capital and resource allocation. Previously KPMG and \$3bn fund of hedge

Heejae Chae

Non-executive Director

Experienced public company director. Former CEO of AIM-listed Scapa Group plc, a global supplier of products for healthcare and industrial markets.

Anita Kidgell

Non-executive Director 25 years of pharmaceutical experience. Head of Corporate Strategy at GSK leading strategic initiatives in China, ESG, geopolitics, integrations and demergers.





David Baynes

Chief Financial and Operating Officer

Finance and venture background, long track record of working successfully with the Boards of investee companies Co-founder Fusion IP plc.; bought by IP Group.

Dr Caroline Brown

Non-executive Director

Background in corporate finance, advising global corporations and governments. Experience in managing early stage companies in energy and tech sectors.

Angela Leach

Company Secretary and Group Legal Counsel Background in corporate, commercial and IP law. Previously CMS Cameron McKenna and Memery Crystal.



4 Executive Committee.



Greg Smith Chief Executive Officer See bio on previous page.



Dr Mark Reilly

Managing Partner, Technology Background in software, web, optics, and electronics. Previously Remarkable Innovation, a technical due diligence company with a Fortune 500 and national government clients.



Liz Vaughan-Adams

Director of Communications Background in crisis management, M&A, IPOs, fund raisings, media relations, CSR and digital strategies.



Anthony York Group People Director

Proven capability of developing and leading high-performing teams. Specialising in development of both HR and Reward strategies that directly support commercial growth objectives.









Dr Sam Williams

David Baynes

See bio on previous page.

Managing Partner, Life Sciences 20 years experience in biotech, both as equity analyst and entrepreneur. Co-founder: Istesso

Chief Financial and Operating Officer

Board member: Pulmocide Ltd, Diurnal Group plc, Psioxus Ltd and Microbiotica Limited.

Moray Wright

CEO Parkwalk Advisors

20 years experience with corporate and financial institutions and sits on the board of several Parkwalk companies.

Previously: Hoare Govett, JP Morgan, Lazard and Mirabaud.



Angela Leach

Company Secretary and Group Legal Counsel See bio on previous page.



Chris Glasson Group Finance Director Chartered accountant with 15 years+ experience in finance. Previously: Deloitte, Tesco, The Carphone Warehouse.

Joyce Xie



Managing Director, Global Capital International career in investment management and investment banking. Previously: HSBC investment banking, portfolio management.




5 Shareholder Register (Above 2% Holders).

Shareholder	% holding
Railways Pension Scheme	15.7%
Lombard Odier	7.4%
BlackRock	4.7%
Vanguard	4.5%
Baillie Gifford	4.2%
Schroder Investment Management	3.9%
Imperial College	2.9%
abrdn	2.9%
Lansdowne Partners	2.7%
Border to Coast	2.6%
Legal & General Investment Management	2.4%
Telstra Super	2.3%

*Source: RD:IR database as at 29 February 2024 and TR1 filings




6 Subsector focus and example holdings.





7 Top 10 holdings and fair value movement 2023.



Fair value movements include both realised and unrealised movements and FX





Visionary ventures for a future made possible by science.

2nd Floor, 3 Pancras Square, King's Cross, London, NIC 4AG

Tel: +44 (0) 20 7444 0050

Web: www.ipgroupplc.com

